Impact of Rosuvastatin on Risk Markers of Venous Thromboembolism During Systemic Therapy for Advanced Cancer.
Phase of Trial: Phase II
Latest Information Update: 07 Dec 2017
At a glance
- Drugs Rosuvastatin (Primary)
- Indications Deep vein thrombosis; Pulmonary embolism; Venous thromboembolism
- Focus Pharmacodynamics
- Acronyms DISOLVE
- 07 Dec 2017 Status changed from active, no longer recruiting to completed.
- 10 Jun 2017 Biomarkers information updated
- 28 Dec 2015 Planned End Date changed from 1 Sep 15 to 1 Sep 2016 as reported by ClinicalTrials.gov.